603456.SH
九洲药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 15.71
−5.36%Year over year
Reported trailing growth
- Revenue
- +0.8%
- EBITDA
- —
- EBIT
- +9.2%
- EPS
- +5.5%
- Free cash flow
- +79.0%
- Operating cash flow
- +18.4%
Forward estimates
Based on analyst estimates
- Revenue
- +5.9%
- EBITDA
- +14.0%
- EPS
- +34.5%
Three-year CAGR
- Revenue
- +0.4%
- EBITDA
- -2.6%
- EBIT
- -5.8%
- Net income
- -7.5%
- EPS
- -9.6%
- Free cash flow
- +31.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026